Aclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

Aclaris Therapeutics

Thu 14:18

Aclaris Therapeutics, Inc. ACRS.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended September 30, identical to the same quarter last year.  The mean expectation of eleven analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -21 cents to -15 cents per share.
Revenue fell 55.1% to $1.48 million from a year ago; analysts expected $1.30 million. 
Aclaris Therapeutics, Inc.'s reported EPS for the quarter was a loss of 12 cents​.
The company reported a quarterly loss of $18.51 million.
Aclaris Therapeutics, Inc. shares had fallen by 30.0% this quarter and gained 22.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Aclaris Therapeutics, Inc. is $9.50, about 61.3% above its last closing price of $3.68
This summary was machine generated from LSEG data November 5 at 02:18 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.16
-0.12
Beat
Jun. 30 2026 
-0.16
-0.15
Beat
Mar. 31 2026 
-0.16
-0.15
Beat
Dec. 31 2025 
-0.15
-0.16
Missed